{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06299761",
            "orgStudyIdInfo": {
                "id": "BBI-825-101"
            },
            "organization": {
                "fullName": "Boundless Bio",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications",
            "officialTitle": "An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-825 and BBI-825 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Resistance Gene Amplifications",
            "acronym": "STARMAP",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-the-rnr-inhibitor-bbi-in-subjects-with-tumors-with-resistance-gene-amplifications"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-26",
            "studyFirstSubmitQcDate": "2024-03-07",
            "studyFirstPostDateStruct": {
                "date": "2024-03-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Boundless Bio",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-825 administered as a single agent and in combination with select targeted therapies.",
            "detailedDescription": "BBI-825 will be administered orally (PO) twice daily (BID) to subjects with locally advanced or metastatic non-resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor"
            ],
            "keywords": [
                "Amplification",
                "Oncogene Amplification",
                "ribonucleotide reductase inhibitor",
                "RNR inhibitor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "BBI-825 single agent dose escalation",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 42,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Single Agent Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Single agent BBI-825, administered orally, twice daily, in 28-day cycles",
                    "interventionNames": [
                        "Drug: BBI-825"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BBI-825",
                    "description": "Oral RNR inhibitor",
                    "armGroupLabels": [
                        "Single Agent Dose Escalation"
                    ],
                    "otherNames": [
                        "ribonucleotide reductase inhibitor"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-825",
                    "description": "TEAEs will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.",
                    "timeFrame": "Start of Cycle 1 until 30 days following last dose (each cycle is 28 days)"
                },
                {
                    "measure": "Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of BBI-825",
                    "description": "The MTD and/or RP2D of BBI-825 will be determined.",
                    "timeFrame": "Start of Cycle 1 until 30 days following last dose (each cycle is 28 days)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum observed plasma concentration (Cmax) of BBI-825",
                    "description": "Maximum observed plasma concentration (Cmax) of BBI-825 will be determined.",
                    "timeFrame": "Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)"
                },
                {
                    "measure": "Trough observed plasma concentration (Ctrough) of BBI-825",
                    "description": "Trough observed plasma concentration (Ctrough) of BBI-825 will be determined.",
                    "timeFrame": "Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)"
                },
                {
                    "measure": "Time to Cmax (Tmax) of BBI-825",
                    "description": "Time to Cmax (Tmax) of BBI-825 will be determined.",
                    "timeFrame": "Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)"
                },
                {
                    "measure": "Area under the concentration time curve (AUC) of BBI-825",
                    "description": "Area under the concentration time curve (AUC) of BBI-825 will be determined.",
                    "timeFrame": "Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)"
                },
                {
                    "measure": "Anti-tumor activity of BBI-825 as determined by RECISTv1.1",
                    "description": "Number of participants achieving a best response of progressive disease, stable disease, partial response, or complete response.",
                    "timeFrame": "Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced or metastatic non-resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists,\n* Availability of FFPE tumor tissue, archival or newly obtained,\n* Measurable disease as defined by RECIST Version 1.1,\n* Adequate hematologic function,\n* Adequate hepatic and renal function,\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1,\n* Other inclusion criteria per study protocol.\n\nExclusion Criteria:\n\n* Prior exposure to a selective RNR inhibitor (Note: Prior exposure to chemotherapies with nonselective RNR inhibitory activity e.g., gemcitabine is permitted),\n* Receipt of any approved or considered standard of care anticancer drug(s) or biological product(s) within 4 weeks or 5 half-lives,\n* Hematologic malignancies,\n* Primary CNS malignancy, leptomeningeal disease, or symptomatic active CNS metastases, with exceptions per study protocol,\n* Prior or concurrent malignancies, with exceptions per study protocol,\n* History of HBV, HCV, or HIV infection,\n* Clinically significant cardiac condition,\n* Active or history of interstitial lung disease (ILD) or pneumonitis, or history of ILD or pneumonitis requiring steroids or other immunosuppressive medications,\n* QTcF \\> 470 msec,\n* Concurrent use of strong inhibitors or inducers of CYP3A, CYP2C8, CYP2C9, or CYP2C19,\n* Other exclusion criteria per study protocol.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sara Weymer",
                    "role": "CONTACT",
                    "phone": "16198211090",
                    "email": "ClinicalDevelopment@boundlessbio.com"
                },
                {
                    "name": "Swadesh Sharma",
                    "role": "CONTACT",
                    "phone": "16198211090",
                    "email": "ClinicalDevelopment@boundlessbio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Klaus Wagner, MD",
                    "affiliation": "Boundless Bio",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sarcoma Oncology Research Center",
                    "status": "RECRUITING",
                    "city": "Santa Monica",
                    "state": "California",
                    "zip": "90403",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.01945,
                        "lon": -118.49119
                    }
                },
                {
                    "facility": "START Midwest",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}